[{"from": "human", "value": "Please give me some details about this molecule. [C][C][C][=Branch1][C][=O][N][Branch2][Branch1][Ring1][C@@H1][Ring1][=Branch1][C][=Branch1][C][=O][N][Branch1][N][C][=C][C][=Branch1][=Branch1][=C][N][=C][Ring1][=Branch1][F][C@@H1][Branch1][#Branch2][C][=C][C][=C][C][=C][Ring1][=Branch1][Cl][C][=Branch1][C][=O][N][C][C][C][Branch1][Ring2][C][Ring1][Ring2][Branch1][C][F][F][C][=N][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][#N]"}, {"from": "gpt", "value": "The molecule is a tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. It has a role as an antineoplastic agent and an EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor. It is a member of monochlorobenzenes, a cyanopyridine, a member of pyrrolidin-2-ones, an organofluorine compound, a tertiary carboxamide and a secondary carboxamide."}]